The U.S. health authorities are intensifying their scrutiny of compounded weight-loss medications, particularly targeting Hims & Hers for its introduction of a cheaper version of the popular GLP-1 drug, Wegovy. The company, which has seen its stock tumble amidst growing concerns, now faces a referral to the Justice Department from the Health and Human Services (HHS) for its practices. In response to these developments, Novo Nordisk, the manufacturer of Wegovy, has threatened legal action against Hims & Hers, labeling its compounded version as illegal and risky. The FDA has signaled plans to restrict GLP-1 ingredients in non-approved drugs, heightening the tension in the weight-loss drug market. As Hims & Hers continues to promote its $49 pill, both consumers and investors remain wary about the implications of this escalating drug controversy.